ISORAY, INC. (NYSEMKT:ISR) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition |
On May 10, 2017, IsoRay, Inc. (the Company) issued a press
release announcing its financial results for the third quarter of
fiscal 2017, ended March 31, 2017, the text of which is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Current Report on Form 8-K, including the
exhibit, is furnished to Item2.02 and shall not be deemed filed
for the purposes of Section18 of the Securities Exchange Act of
1934, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, except as shall be
expressly set forth by specific reference in such filing.
| Item9.01. | Financial Statements and Exhibits |
(d) Exhibits
|
Exhibit |
Description | |
| 99.1 | Press release issued by IsoRay, Inc., dated May 10, 2017. |
About ISORAY, INC. (NYSEMKT:ISR)
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. ISORAY, INC. (NYSEMKT:ISR) Recent Trading Information
ISORAY, INC. (NYSEMKT:ISR) closed its last trading session up +0.002 at 0.570 with 58,914 shares trading hands.